RESEARCH Q&A
Frequently asked questions
Common questions about the three compounds on this desk, answered from published data — not community lore.
What is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid hexadecapeptide modelled on residues 177–191 of the C-terminal domain of human growth hormone, with a tyrosine substituted at the N-terminus. It was developed as an oral anti-obesity drug candidate by Metabolic Pharmaceuticals. It is not FDA-approved, not a supplement, and is classified as WADA-prohibited S2 at all times in sport [3][2].
What does the peptide AOD9604 do?
In the mechanistic literature, AOD-9604 inhibits acetyl-CoA carboxylase (the rate-limiting enzyme in fatty acid synthesis) and up-regulates beta-3 adrenergic receptor expression in white adipose tissue, increasing fat oxidation — effects documented in rodent models and cell preparations [4][5][6][7]. It does not bind the growth hormone receptor. In humans, it was well tolerated but did not produce statistically significant weight loss versus placebo across the Phase IIb trial programme [3].
Does AOD-9604 actually work?
On the primary clinical endpoint — statistically significant weight loss versus placebo in humans — the answer from the published Phase IIb programme (approximately 900 subjects, up to 24 weeks) is no [3]. The development programme was discontinued after that result. The rodent fat-loss data are real [4][5], but those mechanistic findings did not translate into an efficacy signal in the human trials. Community reports are consistent with the trial finding: the most common report is no noticeable fat loss.
How does AOD-9604 work?
The proposed mechanism has two components: (1) inhibition of acetyl-CoA carboxylase via a membrane-derived second messenger, suppressing de novo lipogenesis [7]; and (2) upregulation of beta-3 adrenergic receptor expression in white adipose tissue during chronic dosing, amplifying fat oxidation [4]. Acute increases in energy expenditure were observed in beta3-AR knockout mice even without the receptor, but the chronic fat-loss effect required functional beta3-AR signaling [4]. The growth hormone receptor is not engaged.
What is tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide — the first dual GIP/GLP-1 receptor agonist — FDA-approved for type 2 diabetes mellitus (May 2022), chronic weight management in adults with obesity or overweight plus a weight-related complication (November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity. It is a prescription medicine, not a research-only compound [9].
How does tirzepatide work?
Tirzepatide co-activates two incretin receptors: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). GLP-1 receptor activation suppresses glucagon, slows gastric emptying, and reduces appetite. GIP receptor activation enhances glucose-dependent insulin secretion. Engaging both pathways simultaneously produces larger glycaemic and weight-loss effects than selective GLP-1 receptor agonism alone, as demonstrated in direct head-to-head trials [8][12].
What does tirzepatide do in the body?
Tirzepatide increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and markedly reduces appetite and caloric intake. In the SURMOUNT-1 Phase 3 RCT (n=2,539), mean body weight at 72 weeks declined by −20.9% at the 15 mg dose versus −3.1% with placebo. In the SURPASS-2 diabetes trial (n=1,879), HbA1c was reduced by 2.01–2.30 percentage points versus 1.86 pp with another incretin [11][12].
What is tirzepatide used for?
In its FDA-approved indications, tirzepatide is used to improve glycaemic control in adults with type 2 diabetes mellitus, for chronic weight management in adults with obesity or overweight plus a weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. All uses are prescription-only. This desk does not discuss off-label or unapproved uses, and does not recommend or facilitate acquisition of prescription medication [9].
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that, in preclinical models, activates AMPK by disrupting the folate cycle and accumulating AICAR, improving skeletal-muscle glucose uptake and insulin sensitivity [15]. Under metabolic stress it also translocates to the nucleus and regulates antioxidant and metabolic gene expression [17]. In aged mice, exogenous administration significantly increased physical performance (treadmill capacity, grip strength, gait) [16]. In humans, the only published data are observational biomarker associations — no interventional human trial data exist [14].
What are the negative side effects of MOTS-c?
No human interventional safety data for exogenous MOTS-c have been published. The compound is not FDA-approved and human pharmacokinetics have not been established in peer-reviewed literature. Research preparations are unregulated for pharmaceutical-grade purity and identity. A genetic variant in the MT-RNR1 locus (m.1382A>C) is associated with a pro-diabetogenic phenotype in some populations, suggesting modulating this pathway may carry ancestry-dependent risks [15]. MOTS-c is treated as prohibited by WADA and USADA in elite sport.
Is MOTS-c legal to buy?
In most jurisdictions, MOTS-c is not a controlled substance, and research-chemical suppliers sell it for laboratory use only. However, its legal status varies by country, and purchasing, possessing, or using it for human administration may violate domestic therapeutic-goods or food-and-drug laws. It is not a regulated pharmaceutical in any jurisdiction. Athletes subject to WADA or USADA rules should be aware that it is treated as prohibited at all times and that this desk cannot provide legal advice.
How often do you inject MOTS-c?
This desk does not provide dosing, protocol, or administration guidance for any compound. There is no peer-reviewed human dose-response or pharmacokinetic data for MOTS-c that would support any dosing recommendation. Rodent doses in published studies (0.5–15 mg/kg/day) cannot be extrapolated to humans. The question of how often any research chemical should be administered is one this site is not in a position to answer [15][16].